# US 2025/0360101 A1 · Osteoclast differentiation inhibitor containing urolithin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0360101 A1
- Document ID: US20250360101A1
- Status: Published application
- Kind: A1
- Application number: 19/296,658
- Filed: 2025-08-11
- Published: 2025-11-27
- Earliest claimed: 2020-08-19
- Assignees: Daicel Corporation
- Applicants: Daicel Corporation
- Inventors: Kenji KOBATA; Sachie NAKATANI; Masatake KUDOH
- Web page: https://patentgrep.com/patent/US20250360101A1

## CPC

- A61K 31/37: Coumarins, e.g. psoralen
- A23L 2/52: Adding ingredients (adding preservatives A23B70/10)
- A23L 33/30: {Dietetic or nutritional methods, e.g. for losing weight (A23L33/10 takes precedence)}
- A61K 8/498: {having 6-membered rings or their condensed derivatives, e.g. coumarin}
- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61P 19/10: for osteoporosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

An object of the present invention is to provide an effective and highly safe agent for inhibiting osteoclast differentiation, and a food or drink, pharmaceutical, supplement, and cosmetic that produce an osteoclast differentiation-inhibiting effect; and the object is fulfilled by an agent for inhibiting osteoclast differentiation, comprising a urolithin.

## Claims

### Claim 1

A method for inhibiting osteoclast differentiation, the method comprising:
administering a composition to an individual having osteoporosis, the composition comprising urolithin that is 0.0001% to 10% by mass of the composition, and administered in an effective amount that reduces a number of the osteoclasts; and
inhibiting differentiation of hematopoietic stem cells into osteoclasts in the individual.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the composition is a food or drink.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the composition is a cosmetic.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the composition is a supplement.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the urolithin is urolithin A and/or urolithin B.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the urolithin is 0.01% to 1% by mass of the composition.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the urolithin is 0.01% to 0.1% by mass of the composition.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the administering treats or prevents a bone disease.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the bone disease decreases bone mass.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the bone disease comprises osteoporosis.

### Claim 11 (depends on 9)

The method according to claim 9, wherein the bone disease comprises bone metastasis.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the urolithin is a powder.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the powder is dissolved in water or ethanol.

### Claim 14 (depends on 1)

The method according to claim 1, wherein the composition comprises an excipient.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the excipient is dextrin, corn starch, or gum arabic.

### Claim 16 (depends on 1)

The method according to claim 1, the method further comprising the step of evaluating the osteoclast differentiation using cell staining.

### Claim 17

A method for preventing or treating osteoporosis, the method comprising administering a prophylactically or therapeutically effective amount of a urolithin to a human.

### Claim 18 (depends on 17)

The method according to claim 17, wherein the urolithin is urolithin A and/or urolithin B.
